抗NXP-2自身抗体与皮肌炎患者水肿、肌肉疾病及恶性肿瘤风险的关系
该研究纳入235例皮肌炎患者,其中56例(23.8%)抗NXP-2抗体阳性。抗NXP-2阳性患者更常见远端手臂、远端腿部及颈部无力,以及吞咽困难、肌痛、钙质沉着和皮下水肿。抗NXP-2阳性者中5例(9%)为肿瘤相关性肌炎,癌症风险较一般人群预期患病率增加3.68倍(95%CI 1.2-8.6)。
要点
- 抗NXP-2阳性皮肌炎患者更易出现远端肢体和颈部无力、吞咽困难、肌痛、钙质沉着及皮下水肿。
- 抗NXP-2阳性与肿瘤相关性肌炎相关,癌症风险较一般人群预期增加3.68倍(95%CI 1.2-8.6)。
- 建议抗NXP-2阳性皮肌炎患者接受全面的癌症筛查。
核心结论
- 在皮肌炎中,抗NXP-2自身抗体与皮下水肿、钙质沉着及以肌痛、近端和远端无力、吞咽困难为特征的肌肉表型相关。
- 抗NXP-2阳性患者癌症风险增加,建议进行全面的癌症筛查。
研究设计与样本
- 研究纳入235例接受抗NXP-2自身抗体检测的皮肌炎患者,比较抗体阳性与阴性患者的临床特征(包括肌力)。
- 将抗NXP-2阳性受试者中观察到的癌症例数与一般人群预期例数进行比较。
主要发现
- 235例皮肌炎患者中56例(23.8%)抗NXP-2抗体阳性。
- 抗NXP-2阳性与阴性患者近端肢体无力患病率无显著差异。
- 抗NXP-2阳性患者远端手臂无力(35% vs 20%;P=0.02)、远端腿部无力(25% vs 8%;P<0.001)和颈部无力(48% vs 23%;P<0.001)更常见。
- 抗NXP-2阳性患者更常见吞咽困难(62% vs 35%;P<0.001)、肌痛(46% vs 25%;P=0.002)、钙质沉着(30% vs 17%;P=0.02)和皮下水肿(36% vs 19%;P=0.01)。
- 5例抗NXP-2阳性受试者(9%)为肿瘤相关性肌炎,癌症风险较一般人群预期患病率增加3.68倍(95%CI 1.2-8.6)。
关键数值与推荐
- 抗NXP-2阳性患者远端手臂无力35% vs 20%(P=0.02)。
- 抗NXP-2阳性患者远端腿部无力25% vs 8%(P<0.001)。
- 抗NXP-2阳性患者颈部无力48% vs 23%(P<0.001)。
- 抗NXP-2阳性患者吞咽困难62% vs 35%(P<0.001)、肌痛46% vs 25%(P=0.002)、钙质沉着30% vs 17%(P=0.02)、皮下水肿36% vs 19%(P=0.01)。
- 抗NXP-2阳性患者肿瘤相关性肌炎9%,癌症风险增加3.68倍(95%CI 1.2-8.6)。
临床怎么用
- 对皮肌炎患者检测抗NXP-2抗体有助于识别以远端无力、吞咽困难、肌痛、钙质沉着和皮下水肿为特征的临床表型。
- 抗NXP-2阳性皮肌炎患者应接受全面的癌症筛查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Dermatomyositis (DM) patients typically present with proximal weakness and autoantibodies that are associated with distinct clinical phenotypes. We observed that DM patients with autoantibodies recognizing the nuclear matrix protein NXP-2 often presented with especially severe weakness. The aim of this study was to characterize the clinical features associated with anti-NXP-2 autoantibodies. METHODS: There were 235 DM patients who underwent testing for anti-NXP-2 autoantibodies. Patient characteristics, including muscle strength, were compared between those with and without these autoantibodies. The number of cancer cases observed in anti-NXP-2-positive subjects was compared with the number expected in the general population. RESULTS: Of the DM patients, 56 (23.8%) were anti-NXP-2-positive. There was no significant difference in the prevalence of proximal extremity weakness in patients with and without anti-NXP-2. In contrast, anti-NXP-2-positive patients had more prevalent weakness in the distal arms (35% versus 20%; P = 0.02), distal legs (25% versus 8%; P < 0.001), and neck (48% versus 23%; P < 0.001). Anti-NXP-2-positive subjects were also more likely to have dysphagia (62% versus 35%; P < 0.001), myalgia (46% versus 25%; P = 0.002), calcinosis (30% versus 17%; P = 0.02), and subcutaneous edema (36% versus 19%; P = 0.01) than anti-NXP-2-negative patients. Five anti-NXP-2-positive subjects (9%) had cancer-associated myositis, representing a 3.68-fold increased risk (95% confidence interval 1.2-8.6) compared to the expected prevalence in the general population. CONCLUSION: In DM, anti-NXP-2 autoantibodies are associated with subcutaneous edema, calcinosis, and a muscle phenotype characterized by myalgia, proximal and distal weakness, and dysphagia. As anti-NXP-2-positive patients have an increased risk of cancer, we suggest that they undergo comprehensive cancer screening.
引用
- Albayda J, Pinal-Fernandez I, Huang W, et al. Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients. Arthritis Care Res (Hoboken). 2017. PMID: 28085235. doi:10.1002/acr.23188
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。